• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Patricia Coyle: Ofatumumab Has the Benefit of Being Taken at Home

Video

The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.

Ofatumumab was recently approved to treat relapsing forms of multiple sclerosis (MS), making it a direct competitor of ocrelizumab; the biggest difference between the 2 therapies is that ofatumumab can be taken at home, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.

Transcript

Ofatumumab was recently approved for relapsing forms of multiple sclerosis. How does it fit into the treatment landscape for patients with MS?

Ofatumumab is a human anti-CD20. As an MS anti-CD20, it is a high-efficacy monoclonal agent. It will be a direct competitor for ocrelizumab, the humanized anti-CD20. Probably the biggest difference is that ofatumumab is given by a subcutaneous monthly injection every 4 weeks and can be delivered at home. This is after a 20 milligram, 3 times over 2 weeks loading dose, and then it's 20 milligrams [subcutaneously] every 4 weeks. That's in contrast to ocrelizumab, which is given intravenously every 6 months.

So, I think you have now a choice between 2 anti-CD20s that are high-efficacy, relatively safe options. One you come to an infusion center twice a year, the other you inject at home subcutaneously monthly.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.